Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Glaucoma Market’s Growth Trajectory From 2025 To 2034?
The market size for glaucoma has seen robust growth in the past few years. The market is anticipated to expand from a $7.76 billion valuation in 2024 to around $8.2 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.6%. The surge in growth during the historical period can be traced back to factors such as greater understanding of eye health, an increase in healthcare expenditures, wider acceptance of telemedicine for eye care, growth in healthcare infrastructure, and larger scale government healthcare initiatives.
In the coming years, the glaucoma market is set to experience significant expansion. By 2029 it is projected to reach a value of$10.12 billion”, increasing at a compound annual growth rate (CAGR) of 5.4%. This anticipated progression in the forecast period is linked to a growing elderly population, increased instances of glaucoma, an escalating demand for less-invasive surgical procedures, heightened occurrences of diabetes, and the rise in hypertension rates. Prominent trends in the projected period encompass advances in diagnostic technologies, the presence of novel drug treatments, technological developments in surgical devices, the offering of combination therapies, and the embrace of robotic surgeries.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp
What Are the Core Market Drivers Propelling Growth in the Glaucoma Industry?
The glaucoma market is expected to grow due to the increasing prevalence of chronic eye conditions. These are long-lasting disorders that negatively impact the eyes, frequently resulting in lasting vision impairment or irritation and necessitating continuous care or treatment. There is an increase in chronic eye conditions due to factors such as an aging population, longer screen time, lifestyle choices, and larger instances of diseases like diabetes and hypertension. An effective glaucoma treatment is necessary to lower intraocular pressure, prevent additional optic nerve damage, and maintain vision, since untreated glaucoma can result in permanent blindness. For example, the National Health Service (NHS), a publicly funded healthcare system in the UK, reported in December 2024 that over 2 million individuals in the UK were living with sight loss. Additionally, they projected that the number of people suffering from sight loss would surge by 27%, totaling around 2.8 million by 2035. Consequently, the glaucoma market is being influenced by the increasing number of chronic eye conditions.
How Is the Glaucoma Market Segmented?
The glaucomamarket covered in this report is segmented –
1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
4) By Administration: Oral; Injections; Intravitreal; Other Administrations
5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp
Which Regions Are Driving the Next Phase of the Glaucoma Market Growth?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Glaucoma Industry?
In the glaucoma market, leading corporations are concentrating on the creation of novel treatments, such as Rho-kinase (ROCK) inhibitors. These therapies offer a two-pronged approach by lessening intraocular pressure through both improving the effusion of aqueous humor and relaxing trabecular meshwork cells. This makes them a potent solution for glaucoma treatment. ROCK inhibitors are a type of medication that obstructs the activity of Rho-kinase enzymes that control cell contraction and help alleviate glaucoma by lessening intraocular pressure. For instance, Santen Pharmaceutical Co. Ltd., a Japan-based enterprise specializing in eye care products, introduced Roclanda in the UK in July 2023. Roclanda is a singular combination of latanoprost and netarsudil, a new Rho-kinase (ROCK) inhibitor that effectively reduces intraocular pressure by addressing the dysfunction of the trabecular meshwork. It is meant for adult patients suffering from primary open-angle glaucoma or ocular hypertension who have not seen sufficient IOP reduction with the use of a prostaglandin or netarsudil alone. The release of Roclanda in Europe signifies the introduction of the first new category of glaucoma medication in a quarter-century, representing a significant advancement in treatment. Roclanda, by integrating netarsudil and latanoprost, works in harmony to enhance outflow through both traditional (trabecular) and non-traditional (uveoscleral) paths, thereby offering a comprehensive strategy to control elevated IOP.
View the full report here:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report
How Is the Glaucoma Market Defined and What Are Its Core Parameters?
Glaucoma is a group of eye disorders that cause damage to the optic nerve, typically resulting from increased intraocular pressure (IOP). This damage can lead to progressive, irreversible vision loss if untreated, making glaucoma one of the leading causes of blindness worldwide. Glaucoma is a leading cause of blindness worldwide, and early detection through regular eye exams is critical to prevent vision loss.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model